DMC Biotechnologies

Based in Colorado, DMC Biotechnologies uses a proprietary process to produce bio-based chemical intermediates for pharmaceutical applications, nutritional supplements and detergents. The company’s proprietary process—“Dynamic Metabolic Control” (DMC) is a two-step microbial fermentation process that involves growing biomass and uses “gene-silencing” and “targeted proteolysis” technologies to break them down to create the desired bio-based chemical product. 

As of March 2022,  the company has launched a bio-based amino acid chemical intermediate called “L-Alanine”, for pharmaceutical applications and as detergents. DMC reports that it is also actively developing other bio-based products such as Xylitol (an artificial sweetener for use in food and personal care products) and a branched-chain amino acid (BCAA) for use in animal feed. The company reported that it is working with customers to understand demand and scale production to commercialize its BCAA product as  of February 2022. In November 2023, the company announced a new facility in North Carolina that will be the base for its workflows in strain and metabolic engineering, high throughput testing, and bench and pilot-scale fermentation.

Key customers and partnerships

DMC entered into a manufacturing agreement with Conagen, a Massachusetts-based biotechnology company making ingredients for food, pharmaceutical and renewable industries, for the commercial production of L-alanine (March 2021). The company also partnered with EW Biotech, a German biotechnology company offering to scale up solutions, and was successful in commercially scaling its DMC process for L-Alanine using a 85 cubic meter fermentation tank at EW Biotech’s facility (March 2021). In June 2024, the company partnered with Danone, Michelin and Crédit Agricole to launch a precision fermentation center.